Phase 3 LEAP-012 Trial Offers A New Option for Intermediate-Stage HCC Management
September 17th 2024The trial demonstrated that the combination of lenvatinib, pembrolizumab, and transarterial chemoembolization (TACE) significantly improves progression-free survival and objective response rates compared to TACE alone.
Read More
The DETECT V Trial: Exploring Chemotherapy-Free Treatment for HER2+/HR+ Metastatic Breast Cancer
September 16th 2024Data from the second interim analysis of the DETECT V trial, presented at ESMO Congress 2024, suggest that a chemotherapy-free regimen combining dual HER2-targeted therapy with endocrine therapy, particularly with the addition of ribociclib, may be an effective treatment for patients.
Read More
Rising Incidence of Young-Onset Cancer: Exploring the Causes and Generational Risk Factors
September 16th 2024At ESMO Congress 2024, Shuji Ogino, MD, PhD, MS, explained that the rising incidence of young-onset cancer may be due to generational risk factors such as lifestyle, diet, and environmental changes, emphasizing the need for long-term research and follow up to understand early-life influences on cancer development.
Read More